Tulisokibart
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Overview
Tulisokibart is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Tulisokibart clinical trials
Explore related
Medical disclaimer. This page summarizes research about Tulisokibart for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.